AbbVie (ABBV) Company Description: AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and ...

At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

Migraines affect nearly 40 million people in the U.S. alone, and symptoms like headache, nausea and light sensitivity can often disrupt attendance and performance at work and school. In fact ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (NYSE:ABBV) with a Outperform ...

AbbVie's successful pivot away from Humira isn't the only reason retail investors should consider adding the shares to their portfolios. The company estimates that in 2026, its oncology portfolio ...

A splashy recent acquisition by the company might not be panning out. Just before the market open on Monday, AbbVie revealed that its emraclidine schizophrenia treatment did not meet its primary ...

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer NORTH CHICAGO, Ill.

Rhineland-Palatinate, speaks at the official ground-breaking ceremony for the construction of a new research and development building on the premises of the pharmaceutical company AbbVie.

AbbVie’s ABBV stock declined almost 11% in ... while also signing some early-stage deals in oncology and neuroscience areas. In 2024, it acquired smaller biotechs like Landos Biopharma and ...